Biopharma AI
By
Will Novartis’s $12 Billion Avidity Deal Ignite a New Era of AI-Powered RNA Therapeutics and Transform Rare-Disease Innovation?
Key Insights:• Novartis AG acquires Avidity Biosciences for $12 billion (USD 72 per share) — the company’s largest…
Can Eli Lilly and NVIDIA’s AI Supercomputer Redefine Drug Discovery Timelines and Ignite a $40 Billion AI-Biopharma Revolution?
Key Insights:• Lilly builds one of pharma’s first NVIDIA-powered DGX SuperPODs, training AI on millions of experiments to…
Could the Algen Biotechnologies – AstraZeneca $555 Million AI-Driven Drug-Discovery Pact Redefine How Immunology Therapies Are Developed?
Key Highlights / Executive Take-aways: Strategic Significance of the PartnershipThe alliance between Algen Biotechnologies and AstraZeneca marks a…
Can Takeda and Nabla Bio’s $1 Billion AI Alliance Redefine the Future of Protein Therapeutics?
Key Highlights: AI Takes Center Stage in Takeda’s R&D RebootAfter narrowing its research focus to small molecules, biologics,…
Inductive Bio and Amgen Collaborate With ARPA-H to Advance AI-Based Alternatives to Animal Toxicology Testing
United States Inductive Bio, a New York–based artificial intelligence company focused on drug discovery, has been awarded up…
Pfizer Celebrates Innovation with 2025 AI Festival
Global – Pfizer hosted its second annual AI Festival Week, bringing together colleagues worldwide to explore the transformative…
